Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study
Table 3
Summary of univariate and multivariate Cox regression models for UC-related hospitalization, colectomy, and clinical secondary loss of response requiring dose escalation during maintenance infliximab or adalimumab therapy.
Univariate hazard ratio [95% CI]
value
Multivariate hazard ratio [95% CI]
value
Hazard ratios for UC-related hospitalization
Early anti-TNF induction within three years of diagnosis
1.83 [0.98–3.43]
0.06
1.66 [0.84–3.30]
0.15
Anti-TNF induction 2009–2014
1.86 [0.96–3.63]
0.07
1.90 [0.96–3.76]
0.07
Mayo endoscopic severity at anti-TNF induction
1.43 [0.92–2.24]
0.11
1.22 [0.77–1.94]
0.40
Hazard ratios for colectomy
Early anti-TNF induction within three years of diagnosis
2.56 [0.80–8.19]
0.11
2.02 [0.57–7.20]
0.28
Mayo endoscopic severity at anti-TNF induction
1.66 [0.76–3.63]
0.20
1.35 [0.58–3.14]
0.49
Hazard ratios for clinical secondary loss of response
Anti-TNF induction 2009–2014
1.65 [0.96–2.82]
0.07
1.95 [1.05–3.61]
0.03
C-reactive protein ≥ 8 mg/L
1.50 [0.88–2.57]
0.14
1.44 [0.78–2.64]
0.24
Mayo endoscopic severity at anti-TNF induction
0.76 [0.54–1.07]
0.12
0.74 [0.50–1.11]
0.15
Concurrent steroids at anti-TNF induction
1.52 [0.88–2.61]
0.13
1.53 [0.82–2.85]
0.19
In univariate analysis, choice of anti-TNF agent, gender, age, disease extent by Montreal classification, endoscopic Mayo severity score at diagnosis, partial Mayo symptom score, and concurrent use of immunomodulators or 5-ASA did not have values < 0.2 and were excluded from the multivariate regression analysis.
